HRT and Contraception in Perimenopause: What You Still Need to Know
HRT does not prevent pregnancy. A guide to contraception during perimenopause alongside HRT, including POP, Mirena, and when you can safely stop.
HRT Does Not Prevent Pregnancy
One of the most critical points any perimenopausal woman using HRT needs to understand is that HRT does not provide contraception. This is a common and understandable misconception. HRT replaces declining hormones to manage symptoms; it does not suppress ovulation. During perimenopause, ovulation continues to occur, albeit irregularly and less predictably. While fertility is significantly reduced compared to the reproductive years, pregnancy is still possible. The oldest natural pregnancy on record occurred at 55, and unplanned pregnancies in perimenopausal women are not rare. They are typically associated with a higher risk of chromosomal abnormalities such as Down syndrome, miscarriage, and pregnancy complications, which makes avoiding unintended pregnancy particularly important for this age group. Yet many women in their 40s assume that irregular periods or menopausal symptoms mean they cannot conceive, and stop using contraception before it is safe to do so. Adding HRT to this picture does not change the underlying biology: if ovulation occurs, fertilisation is possible. Any woman using HRT who could become pregnant needs a separate contraceptive method.
How Long Does Contraception Need to Continue?
The standard guidance in the UK, supported by NICE and the Faculty of Sexual and Reproductive Healthcare (FSRH), is that contraception is needed until two years after the last natural period for women who are under 50, and until one year after the last natural period for women who are 50 or older. Regardless of when the last period occurred, NICE also advises that contraception can generally be stopped at age 55, as spontaneous natural pregnancy is extremely rare beyond that age. The complication during perimenopause is that HRT itself can cause withdrawal bleeds (in sequential regimens) or mask the absence of periods (in continuous combined regimens or when using the Mirena). This makes it difficult to know when the last natural period actually occurred. Women using sequential HRT who have a monthly withdrawal bleed cannot use the timing of that bleed to judge their fertility status, because it is induced by the progestogen rather than reflecting ovarian activity. Women on continuous combined HRT or the Mirena who have no bleeding also cannot rely on the absence of periods as confirmation of menopause. In both cases, following the age-based rules (contraception until 55) is the simplest and safest approach.
Contraceptive Options Compatible with HRT
Not all contraceptive methods are equally compatible with HRT, and some are better suited to the perimenopausal age group than others. The progestogen-only pill (POP), also called the mini-pill, is a straightforward option. It does not interfere with HRT and provides reliable contraception. The most commonly used POP in the UK is desogestrel (Cerazette or its generics), which at the usual dose suppresses ovulation as well as thinning cervical mucus, giving it an efficacy comparable to the combined pill. It is suitable for women who cannot use oestrogen-containing contraceptives. Barrier methods such as condoms and diaphragms are effective when used consistently and carry no hormonal interaction with HRT. The copper IUD (non-hormonal) provides highly effective contraception without interfering with systemic hormonal therapy and can be used alongside any HRT preparation. The Mirena IUS, as discussed elsewhere, is perhaps the most practical combined solution: it provides both the progestogen component of HRT and reliable contraception from a single device. The implant (Nexplanon) is another long-acting option that is progestogen-only and compatible with systemic oestrogen HRT, though it does not provide the endometrial protection needed for women on systemic oestrogen without an additional progestogen source.
Why the Combined Pill Is Not Usually the Answer
Some women in early perimenopause are already using the combined oral contraceptive pill (COCP) and wonder whether to switch to HRT or continue the pill. This is a nuanced clinical question. The COCP does suppress perimenopausal symptoms because it overrides the body's own fluctuating hormones with a consistent synthetic oestrogen and progestogen. In that sense, it manages symptoms. However, the COCP uses ethinylestradiol, a synthetic oestrogen that is substantially more potent than the oestradiol used in HRT, and carries a higher risk of VTE than transdermal HRT. NICE guidance recommends transitioning from the COCP to HRT by the mid-40s for most women, as the risk-benefit balance shifts with age. Crucially, the COCP masks the hormonal picture and makes it impossible to assess where a woman is in her menopausal transition. Women who switch from the COCP often discover significant perimenopausal symptoms emerging as the synthetic hormones clear their system. The COCP used beyond 50 is generally not recommended. Women who want both symptom management and contraception beyond 50 are better served by a combination of HRT and a progestogen-only or non-hormonal contraceptive method.
FSH Testing and Confirming Menopause While on HRT
Follicle-stimulating hormone (FSH) testing is commonly used to assess menopausal status, but it is unreliable in women using hormonal contraception or systemic HRT. Both oestrogen-containing preparations and the COCP suppress FSH to levels that do not reflect the true ovarian reserve or menopausal status. The FSRH advises that FSH testing is only meaningful if a woman stops hormonal contraception for at least six weeks (or four to six weeks after stopping the combined pill). For women on HRT, FSH levels are similarly suppressed and cannot be used to confirm menopause. This means that the timing-based approach (waiting until 12 months after the last natural period for women over 50) is the practical standard. Women who are uncertain about whether they have reached menopause while on HRT can discuss stopping HRT briefly to observe symptoms and period return, though this is obviously not comfortable for everyone. The simplest approach for most women is to continue contraception until 55 regardless of HRT use and testing results, removing the ambiguity entirely. Anti-Mullerian hormone (AMH) testing is occasionally used to assess ovarian reserve but is not currently recommended in guidelines as a tool for timing contraceptive cessation.
Having the Conversation With Your Prescriber
Contraception alongside HRT is a topic that does not always get discussed thoroughly at routine menopause consultations, partly because HRT prescribing and contraceptive prescribing sometimes sit in different clinical domains. It is worth proactively raising both topics together with your GP, nurse prescriber, or menopause specialist. Ask specifically whether your current contraceptive method is appropriate to continue with your HRT regimen, whether your existing contraceptive provides any progestogen cover for HRT purposes, and what your plan should be for stopping contraception when the time comes. Women who are using the Mirena as their progestogen component of HRT have the neatest solution: endometrial protection and contraception from a single device. Women using a POP, copper IUD, or barrier method alongside their HRT should have clarity from their prescriber about when each element of their plan should be reviewed. If you are approaching 50 and still using the combined pill, raising a conversation about switching to HRT plus a separate contraceptive is worthwhile. The Faculty of Sexual and Reproductive Healthcare publishes clear, freely accessible guidelines on contraception use at perimenopause that can be a useful starting point for these conversations.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.